Boston Scientific (NYSE:BSX) Shares Down 5.1% on Analyst Downgrade

Boston Scientific Corporation (NYSE:BSX)’s share price traded down 5.1% on Tuesday after Royal Bank Of Canada lowered their price target on the stock from $100.00 to $85.00. Royal Bank Of Canada currently has an outperform rating on the stock. Boston Scientific traded as low as $42.45 and last traded at $42.39. 4,403,202 shares traded hands during trading, a decline of 75% from the average daily volume of 17,961,764 shares. The stock had previously closed at $44.65.

A number of other analysts have also issued reports on the company. Bank of America decreased their price target on Boston Scientific from $105.00 to $68.00 and set a “buy” rating on the stock in a research note on Monday, May 18th. Leerink Partners dropped their price objective on shares of Boston Scientific from $87.00 to $74.00 and set an “outperform” rating for the company in a research note on Thursday, May 28th. Daiwa Securities Group cut shares of Boston Scientific from a “strong-buy” rating to a “hold” rating in a research report on Wednesday, April 29th. Weiss Ratings downgraded shares of Boston Scientific from a “hold (c-)” rating to a “sell (d+)” rating in a report on Tuesday, July 7th. Finally, Wall Street Zen lowered shares of Boston Scientific from a “buy” rating to a “hold” rating in a research report on Saturday, March 28th. One equities research analyst has rated the stock with a Strong Buy rating, twenty-three have given a Buy rating, four have assigned a Hold rating and two have issued a Sell rating to the stock. According to data from MarketBeat, Boston Scientific has a consensus rating of “Moderate Buy” and a consensus price target of $80.72.

Insider Activity

In other news, Director Edward J. Ludwig acquired 3,580 shares of Boston Scientific stock in a transaction dated Wednesday, May 20th. The shares were acquired at an average cost of $56.68 per share, with a total value of $202,914.40. Following the purchase, the director directly owned 25,359 shares of the company’s stock, valued at approximately $1,437,348.12. This trade represents a 16.44% increase in their position. The acquisition was disclosed in a filing with the Securities & Exchange Commission, which is available at this link. Also, Director David C. Habiger bought 2,250 shares of the company’s stock in a transaction that occurred on Wednesday, May 20th. The shares were acquired at an average cost of $55.92 per share, with a total value of $125,820.00. Following the transaction, the director owned 13,878 shares in the company, valued at approximately $776,057.76. This represents a 19.35% increase in their position. The SEC filing for this purchase provides additional information. Insiders have bought 9,800 shares of company stock valued at $554,012 in the last three months. Corporate insiders own 0.34% of the company’s stock.

Hedge Funds Weigh In On Boston Scientific

A number of hedge funds have recently made changes to their positions in BSX. FWL Investment Management LLC acquired a new stake in Boston Scientific in the 2nd quarter valued at $26,000. Swiss RE Ltd. acquired a new position in shares of Boston Scientific during the fourth quarter worth about $26,000. Garton & Associates Financial Advisors LLC acquired a new position in shares of Boston Scientific during the fourth quarter worth about $26,000. Bangor Savings Bank boosted its position in shares of Boston Scientific by 94.7% in the fourth quarter. Bangor Savings Bank now owns 292 shares of the medical equipment provider’s stock worth $28,000 after buying an additional 142 shares during the period. Finally, Board of the Pension Protection Fund acquired a new stake in shares of Boston Scientific in the fourth quarter valued at about $29,000. Hedge funds and other institutional investors own 89.07% of the company’s stock.

Boston Scientific Trading Down 5.1%

The firm has a market capitalization of $63.01 billion, a PE ratio of 17.72, a P/E/G ratio of 0.86 and a beta of 0.58. The company has a debt-to-equity ratio of 0.42, a quick ratio of 1.22 and a current ratio of 1.90. The firm has a fifty day moving average of $49.15 and a 200 day moving average of $67.13.

Boston Scientific (NYSE:BSX) last released its quarterly earnings results on Wednesday, April 22nd. The medical equipment provider reported $0.80 EPS for the quarter, topping the consensus estimate of $0.79 by $0.01. Boston Scientific had a return on equity of 19.17% and a net margin of 17.29%.The firm had revenue of $5.20 billion for the quarter, compared to analyst estimates of $5.19 billion. During the same period in the previous year, the company posted $0.75 EPS. Boston Scientific’s revenue for the quarter was up 11.6% on a year-over-year basis. Boston Scientific has set its Q2 2026 guidance at 0.820-0.840 EPS and its FY 2026 guidance at 3.340-3.410 EPS. Equities research analysts expect that Boston Scientific Corporation will post 3.36 EPS for the current year.

Boston Scientific declared that its Board of Directors has authorized a stock repurchase plan on Monday, May 18th that permits the company to repurchase $5.00 billion in shares. This repurchase authorization permits the medical equipment provider to repurchase up to 6.4% of its stock through open market purchases. Stock repurchase plans are typically a sign that the company’s management believes its shares are undervalued.

Boston Scientific Company Profile

Boston Scientific Corporation (NYSE: BSX) is a global medical device company that develops, manufactures and markets a broad portfolio of products used in less-invasive medical procedures. Founded in 1979 by John Abele and Peter Nicholas, the company is headquartered in Marlborough, Massachusetts, and focuses on technologies that enable physicians to treat a wide range of cardiovascular, digestive, urologic, pulmonary and chronic pain conditions without open surgery.

Boston Scientific’s activities span product development, clinical research, regulatory affairs and commercial sales.